142 related articles for article (PubMed ID: 10921398)
1. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course?
Shiratori Y; Omata M
J Gastroenterol Hepatol; 2000 May; 15 Suppl():E141-51. PubMed ID: 10921398
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.
Toyoda H; Kumada T; Tokuda A; Horiguchi Y; Nakano H; Honda T; Nakano S; Hayashi K; Katano Y; Nakano I; Hayakawa T; Nishimura D; Kato K; Imada K; Imoto M; Fukuda Y;
J Viral Hepat; 2000 Nov; 7(6):414-9. PubMed ID: 11115052
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
4. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
[TBL] [Abstract][Full Text] [Related]
5. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents.
Huang CM; Hu TH; Chang KC; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hung CH; Cho CL; Wu CK
Medicine (Baltimore); 2017 Nov; 96(46):e8696. PubMed ID: 29145306
[TBL] [Abstract][Full Text] [Related]
6. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
7. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
8. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675
[TBL] [Abstract][Full Text] [Related]
9. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.
Okanoue T; Minami M; Makiyama A; Sumida Y; Yasui K; Itoh Y
Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S89-91. PubMed ID: 16234069
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
11. Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C.
Noritake H; Kobayashi Y; Ooba Y; Matsunaga E; Ohta K; Shimoyama S; Yamazaki S; Chida T; Kawata K; Sakaguchi T; Suda T
J Interferon Cytokine Res; 2015 Dec; 35(12):956-62. PubMed ID: 26308703
[TBL] [Abstract][Full Text] [Related]
12. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
13. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
14. Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.
Shirabe K; Sugimachi K; Harada N; Kayashima H; Maeda T; Tsujita E; Minagawa R; Kajiyama K; Yoshiya S; Maehara Y
Anticancer Res; 2015 Dec; 35(12):6963-9. PubMed ID: 26637923
[TBL] [Abstract][Full Text] [Related]
15. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.
Ishikawa T
World J Gastroenterol; 2008 Oct; 14(40):6140-4. PubMed ID: 18985803
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus.
Yada M; Miyazaki M; Tanaka K; Masumoto A; Motomura K
World J Gastroenterol; 2018 Apr; 24(13):1478-1485. PubMed ID: 29632428
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C.
Omata M; Shiratori Y
J Gastroenterol Hepatol; 2000 May; 15 Suppl():E134-40. PubMed ID: 10921397
[TBL] [Abstract][Full Text] [Related]
19. The impact of antiviral therapy on the course of chronic HCV infection. A systematic review.
Almasio PL; Venezia G; Craxì A
Panminerva Med; 2003 Sep; 45(3):175-82. PubMed ID: 14618115
[TBL] [Abstract][Full Text] [Related]
20. Effects of interferon therapy in "non responder" patients with chronic hepatitis C.
Poynard T; Moussali J; Ratziu V; Regimbeau C; Opolon P
J Hepatol; 1999; 31 Suppl 1():178-83. PubMed ID: 10622583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
